Trial Profile

Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI-1703880 (Primary) ; Ezabenlimab (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Boehringer Ingelheim

Most Recent Events

18 Mar 2025 Planned End Date changed from 8 May 2027 to 13 Sep 2028.
18 Mar 2025 Planned primary completion date changed from 9 Mar 2027 to 13 Sep 2028.
18 Feb 2025 Planned End Date changed from 30 Apr 2027 to 8 May 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com